Replies to post #176548 on Anavex Life Sciences Corp (AVXL)

[nidan7500]

https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpcd/classification.cfm?id=3751

I am still digging but look at FDA 510K granted ref to S/W uses-brain. I am linking this to your earlier observation around the Cognision mother comapny technical officer being named in AVXL patent. Reading the summary of the (not stated) and a read of the AVXL patent posted today I see them describing the process of the AI tool to evaluate/measure ERP results as a method of determining dose efficacy-results. Read AVXL new patent methods and filling in a few blanks for myself. Thanks, will continue to study this.

You can see from the above that the FDA has granted the 510K for the AI device, which I believe is in use for the patent/trial method. Read through the method sequences and see varying doses. Note: they are silent on (then what) but that (interval) is where the tools is used, IMO. Then doses either continue or are changed. Bottom line, I see a process is being used to diagnose for various does levels w/A2-70 and other named compounds. I will be away for a while now. BTW, they may have already done some of this in a lab, IMO.